Mannatech vs USANA Health Sciences
MTEX and USNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MTEX and USNA compare
USANA Health Sciences is the larger company, worth 20 times as much as Mannatech ($245M against $12.2M).
USANA Health Sciences grew revenue faster over the last twelve months (−0.78% versus −6.6% for Mannatech).
Mannatech keeps more of each dollar of sales as profit, with a net margin of −0.41% compared with −2.3% at USANA Health Sciences.
USANA Health Sciences scores higher on the StockData Score (11 against 9 for Mannatech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MTEX | USNA |
|---|---|---|
| Size and price | ||
| Market cap | $12.2M | $245M |
| Share price | $6.30 | $13.24 |
| Change, 1 year | −33.8% | −31.7% |
| Change, 5 years | −83.5% | −87.0% |
| Beta (5Y) | 0.36 | 0.65 |
| Employees | 387 | 1,570 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 0 | 0 |
| Performance score | 4 (better) | 2 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× (better) | 0.3× |
| P/B | 2.3× | 0.5× (better) |
| EV/EBITDA | 4.8× | 2.3× (better) |
| P/FCF | – | 8.3× |
| FCF yield | −5.3% | 12.1% (better) |
| Fair value | $11.41 | $31.52 |
| Margin of safety | 44.8% | 58.0% (better) |
| Growth | ||
| Revenue growth (TTM) | −6.6% | −0.78% (better) |
| Revenue growth, 5Y average | −6.5% | −4.0% (better) |
| Net income growth (TTM) | – | −225% |
| EPS growth (TTM) | – | −231% |
| EPS growth, 5Y average | – | −37.0% |
| Profitability | ||
| Gross margin | 75.7% | 77.3% (better) |
| Operating margin | 0.91% (better) | −0.41% |
| Net margin | −0.41% (better) | −2.3% |
| FCF margin | −0.63% | 3.3% (better) |
| Return on equity | −7.0% | −4.0% (better) |
| Return on invested capital | 17.8% (better) | −0.81% |
| Financial health | ||
| Debt / equity | 0.53 (better) | 0.00 |
| Net debt / EBITDA | −1.36 | – |
| Interest coverage | 2.0× (better) | −9.4× |
| Current ratio | 1.18 | 2.59 (better) |
| Altman Z-score | 4.10 (better) | 3.50 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 7.9% | 66.2% |
| Held by insiders | – | 40.9% |
| Insider net buying, 12 months | $62.2K (better) | −$895K |
| Short interest, % of float | – | 8.1% |
Go deeper
- MTEX stock overview
- MTEX income statement
- MTEX valuation and score
- USNA stock overview
- USNA income statement
- USNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.